Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.49 |
| ▸ | KIF11 | P52732 | 12/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7894551 | 0.98 | SIRT2 (0.48) | SIRT2KIF11HPGDNPC1RAB9A | |
| SCHEMBL5965491 | 0.93 | SIRT2 (0.44) | SIRT2KIF11HPGDNPC1RAB9A | |
| SCHEMBL29032265 | 0.93 | SIRT2 (0.43) | SIRT2KIF11HPGDNPC1RAB9A | |
| SCHEMBL18175275 | 0.92 | SIRT2 (0.43) | SIRT2KIF11HPGDNPC1RAB9A | |
| SCHEMBL21765843 | 0.92 | RAB9A (0.51) | SIRT2HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13555716 | 0.92 | KIF11 (0.44) | SIRT2KIF11HPGDNPC1RAB9A | |
| SCHEMBL13555842 | 0.92 | SIRT2 (0.45) | SIRT2KIF11HPGDSLC6A1SLC6A11 | |
| SCHEMBL19645877 | 0.90 | TAAR1 (0.53) | KIF11HPGDRAB9ASMN1; SMN2ALDH1A1 | |
| Hexanoate SCHEMBL8076130 | 0.87 | HPGD (0.41) | SIRT2KIF11HPGD | |
| SCHEMBL17245967 | 0.85 | KIF11 (0.43) | SIRT2KIF11HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180059072-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYSIS OF MN DIAGNOSTIC AND THERAPEUTIC LIGAND AND PRECURSOR | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, Executive Yuan, R.O.C. (TW) | 2018-03-01 | — | — | US | claimed |
| US-9227931-B1 | Bifunctional compound and method for manufacturing the same | Atomic Energy Council—Institute of Nuclear Energy Research (TW) | 2016-01-05 | — | — | US | claimed |
| US-8329879-B2 | H3LMN compound used as radioactive agent for treatment of liver cancer and manufacturing method thereof | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2012-12-11 | — | — | US | claimed |
| EP-0859641-B1 | DOPAMINE TRANSPORTER IMAGING AGENT | HARVARD COLLEGE (US) | 2012-10-17 | — | — | EP | claimed |
| US-20110065904-A1 | H3LMN COMPOUND USED AS RADIOACTIVE AGENT FOR TREATMENT OF LIVER CANCER AND MANUFACTURING METHOD THEREOF | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2011-03-17 | — | — | US | claimed |
| EP-1051980-B1 | Dopamine transporter imaging agents | HARVARD COLLEGE (US) | 2010-12-15 | — | — | EP | claimed |
| US-20090208415-A1 | Tropane compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-08-20 | — | — | US | claimed |
| US-20070009432-A1 | Boat tropanes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | US | claimed |
| EP-1518562-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-03-30 | — | — | EP | claimed |
| EP-1518561-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-03-30 | — | — | EP | claimed |
| US-20030232819-A1 | Tropane compounds | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-12-18 | — | — | US | claimed |
| US-20020131931-A1 | Boat tropanes | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2002-09-19 | — | — | US | claimed |
| US-6171576-B1 | TROPANE COMPOUND IS LINKED THROUGH THE N ATOM AT THE 8-POSITION TO A CHELATING LIGAND CAPABLE OF COMPLEXING TECHNETIUM OR RHENIUM TO PRODUCE A NEUTRAL LABELED COMPLEX THAT SELECTIVELY BINDS TO THE DOPAMINE TRANSPORTER. | ORGANIX INC. | 2001-01-09 | — | — | US | claimed |
| EP-1051980-A2 | Dopamine transporter imaging agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-11-15 | — | — | EP | claimed |
| EP-1046401-A2 | Fatty acid derivative labelled with a radioactive transition metal | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2000-10-25 | — | — | EP | claimed |
| CN-116406368-A | Conjugated compounds derived from sibs and methods of use thereof | 赖利制药公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20180059072-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYSIS OF MN DIAGNOSTIC AND THERAPEUTIC LIGAND AND PRECURSOR | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, Executive Yuan, R.O.C. (TW) | 2018-03-01 | — | — | US | disclosed |
| EP-0692982-A4 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT MERCK PHARMA (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020131931-A1 | Boat tropanes | SLC6A3, SLC18A2, SLC6A4 | SIRT2 2799/4885KIF11 967/4885HPGD 3255/4885 |
| US-20030232819-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | SIRT2 1841/4885KIF11 1287/4885HPGD 3133/4885 |
| US-20110065904-A1 | H3LMN COMPOUND USED AS RADIOACTIVE AGENT FOR TREATMENT OF LIVER CANCER AND MANUFACTURING METHOD THEREOF | L3MBTL3, LIPC, L3MBTL4 | SIRT2 3263/4885KIF11 1228/4885HPGD 3040/4885 |
| US-20090208415-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | SIRT2 1841/4885KIF11 1287/4885HPGD 3133/4885 |
| US-20070009432-A1 | Boat tropanes | SLC6A3, SLC18A2, SLC6A4 | SIRT2 2799/4885KIF11 967/4885HPGD 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.